Factors influencing warfarin dose requirements in African-Americans

Pharmacogenomics

Volumn 8, Issue 11, 2007, Pages 1535-1544

  Momary, Kathryn M ^a   Shapiro, Nancy L ^c   Viana, Marlos A G ^b   Nutescu, Edith A ^c   Helgason, Cathy M ^b   Cavallari, Larisa H ^c  

^a MERCER UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Anticoagulation; Cytochrome P450 2C9; Genotype; NADPH quinone oxidoreductase; Polymorphisms; Race; Vitamin K epoxide reductase complex subunit 1; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ARGININE; ASPARTIC ACID; CYSTEINE; CYTOCHROME P450 2C9; DRUG METABOLIZING ENZYME; GLUTAMIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOLEUCINE; LEUCINE; MENADIONE EPOXIDE; PROLINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SERINE; SIMVASTATIN; WARFARIN;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ALLELE; ARTICLE; BODY SIZE; BODY SURFACE; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOSITY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POPULATION RESEARCH; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS;

AFRICAN AMERICANS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOOD HABITS; GENE FREQUENCY; GENOTYPE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, SINGLE NUCLEOTIDE; THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 37349123273     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.11.1535     Document Type: Article

References (49)

1. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E: The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl.), 204S-233S (2004).
2. Fihn SD, McDonell M, Martin D et al.: Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin optimized outpatient follow-up study group. Ann. Intern. Med. 118(7), 511-520 (1993).
3. Palareti G. Leali N, Coccheri S: Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet 348 (9025), 423-428 (1996).
4. Absher RK, Moore ME, Parker MH: Patient-specific factors predictive of warfarin dosage requirements. Ann. Pharmacother. 36(10), 1512-1517 (2002).
5. Kamali F, Khan TI, King BP et al.: Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin. Pharmacol. Ther. 75(3), 204-212 (2004).
6. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL: Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost. 91(1), 87-94 (2004).
7. Higashi MK, Veenstra DL, Kondo, LM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13), 1690-1698 (2002).
8. Loebstein R, Yonath H, Peleg D et al.: Interindividual variability in sensitivity to warfarin - nature or nurture? Clin. Pharmacol. Ther. 70(2), 159-164 (2001).
9. Dickmann LJ, Rettie AE, Kneller MB et al.: Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African-Americans. Mol. Pharmacol. 60(2), 382-387 (2001).
10. Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005).
11. Veenstra DL, You JH, Rieder MJ et al.: Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 15(10), 687-691 (2005).
12. Sconce EA, Khan TI, Wynne HA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7), 2329-2333 (2005).
13. D'Andrea G, D'Ambrosio RL, Di Perna P et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105(2), 645-649 (2005).
14. Aquilante CL, Langaee TY, Lopez LM et al.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79(4), 291-302 (2006).
15. Tham LS, Goh BC, Nafziger A et al.: A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin. Pharmacol. Ther. 80(4), 346-355 (2006).
16. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V: The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb. Haemost. 95(5), 782-787 (2006).
17. Takahashi H, Wilkinson GR, Nutescu EA et al.: Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16(2), 101-110 (2006).
18. Kimura R, Miyashita K, Kokubo Y et al.: Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb. Res. 120(2), 181-186 (2007).
19. Cho HJ, Sohn KH, Park HM et al.: Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics 8(4), 329-337 (2007).
20. Caldwell MD, Berg RL, Zhang KQ et al.: Evaluation of genetic factors for warfarin dose prediction. Clin. Med. Res. 5(1), 8-16 (2007).
21. Wallin R, Martin LF: Vitamin K- dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J. Clin. Invest. 76(5), 1879-1884 (1985).
22. Traver RD, Siegel D, Beall HD et al.: Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br. J. Cancer 75(1), 69-75 (1997).
23. Kelsey KT, Ross D, Traver RD et al.: Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br. J. Cancer 76(7), 852-854 (1997).
24. De Haan LH, Boerboom AM, Rietjens IM et al.: A physiological threshold for protection against menadione toxicity by human NAD(P)H:quinone oxidoreductase (NQO1) in Chinese hamster ovary (CHO) cells. Biochem. Pharmacol. 64(11), 1597-1603 (2002).
25. Couris RR, Tataronis GR, Booth SL, Dallal GE, Blumberg JB, Dwyer JT: Development of a self-assessment instrument to determine daily intake and variability of dietary vitamin K. J. Am. Coll. Nutr. 19(6), 801-807 (2000).
26. Hruska MW, Frye RF, Langaee TY: Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes. Clin Chem. 50(12), 2392-2395 (2004).
27. Dreisbach AW, Japa S, Sigel A et al.: The prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African-Americans with hypertension. Am. J. Hypertens. 18(10), 1276-1281 (2005).
28. Marsh S, King CR, Porche-Sorbet RM, Scott-Horton TJ, Eby CS: Population variation in VKORC1 haplotype structure. J. Thromb. Haemost. 4(2), 473-474 (2006).
29. Herman D, Locatelli I, Grabnar I et al.: Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 5(3), 193-202 (2005).
30. Wynne H, Cope L, Kelly P, Whittingham T, Edwards C, Kamali F: The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br. J. Clin. Pharmacol. 40(3), 203-207 (1995).
31. Mungall DR, Ludden TM, Marshall J, Hawkins DW, Talbert RL, Crawford MH: Population pharmacokinetics of racemic warfarin in adult patients. J. Pharmacokinet. Biopharm. 13(3), 213-227 (1985).
32. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE: Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch. Biochem. Biophys. 333(2), 447-458 (1996).
33. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR: Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4(1), 39-42 (1994).
34. Allabi AC, Gala JL, Horsmans Y et al.: Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin. Pharmacol. Ther. 76(2), 113-118 (2004).
35. Limdi NA, McGwin G, Goldstein JA et al.: Influence of CYP2C9 and VKORC1 1173C/T Genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin. Pharmacol. Ther. (2007) (Epub ahead of print).
36. Kealey C, Chen Z, Christie J et al.: Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. Pharmacogenomics 8(3), 217-225 (2007).
37. Morin S, Bodin L, Loriot MA et al.: Pharmacogenetics of acenocoumarol pharmacodynamics. Clin. Pharmacol. Ther. 75(5), 403-414 (2004).
38. Wadelius M, Chen LY, Eriksson N et al.: Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121(1), 23-34 (2007).
39. Chu PH, Huang TY, Williams J, Stafford DW: Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH2. Proc. Natl Acad. Sci. USA 103(51), 19308-19313 (2006).
40. Lee SC, Ng SS, Oldenburg J et al.: Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin. Pharmacol. Ther. 79(3), 197-205 (2006).
41. Schelleman H, Chen Z, Kealey C et al.: Warfarin response and vitamin K epoxide reductase complex 1 in African-Americans and Caucasians. Clin. Pharmacol. Ther. 81(5), 742-747 (2007).
42. Geisen C, Watzka M, Sittinger K et al.: VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost. 94(4), 773-779 (2005).
43. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. 72(6), 702-710 (2002).
44. Shikata E, Ieiri I, Ishiguro S et al.: Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103(7), 2630-2635 (2004).
45. Loebstein R, Vecsler M, Kurnik D et al.: Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin. Pharmacol. Ther. 77(5), 365-372 (2005).
46. Kohnke H, Sorlin K, Granath G, Wadelius M: Warfarin dose related to apolipoprotein E (APOE) genotype. Eur. J. Clin. Pharmacol. 61(5-6), 381-388 (2005).
47. Visser LE, Trienekens PH, De Smet PA et al.: Patients with an ApoE ε4 allele require lower doses of coumarin anticoagulants. Pharmacogenet. Genomics 15(2), 69-74 (2005).
48. Sconce EA, Daly AK, Khan TI, Wynne HA, Kamali F: APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet. Genomics 16(8), 609-611 (2006).
49. Kimmel SE, Christie J, Kealey C et al.: Apolipoprotein E genotype and warfarin dosing among Caucasians and African-Americans. Pharmacogenomics J. (2007) (Epub ahead of print).